cisplatin + nimotuzumab + vinorelbine

This is a combination regimen consisting of three agents: cisplatin, nimotuzumab, and vinorelbine. - **Cisplatin** is a platinum-based chemotherapy that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Nimotuzumab** is a humanized IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated signaling pathways involved in tumor cell proliferation and survival. - **Vinorelbine** is a third-generation vinca alkaloid that inhibits microtubule assembly, blocking mitosis and inducing cell death in cancer cells. This combination has been studied primarily for the treatment of cancers such as non-small cell lung cancer (NSCLC) and cervical cancer, often as part of chemoradiotherapy regimens or first-line therapy for advanced disease[2][3][4][5]. The rationale for combining these agents lies in their complementary mechanisms—targeted inhibition of EGFR with cytotoxic effects from both DNA damage (cisplatin) and mitotic arrest (vinorelbine).

Brand names

nimotuzumab + cisplatin + vinorelbine

Other names

cisplatin plus nimotuzumab plus vinorelbinecisplatin/nimotuzumab/vinorelbine combination